Navigation Links
Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
Date:11/18/2013

Columbus, OH (PRWEB) November 18, 2013

Wright & Schulte LLC is investigating a motion filed on November 5th by 77 plaintiffs in Risperdal gynecomastia lawsuits to Enforce Settlement against Johnson & Johnson (Risperdal Litigation, case number 100300296, In re: Risperdal Litigation, March Term 2010, No. 296). With this motion, the plaintiffs are officially requesting that Judge Arnold New, who is presiding over this litigation, mandate that Johnson & Johnson honor the terms of the settlement the company had reportedly made with these plaintiffs on January 28, 2013.

Wright & Schulte LLC is investigating claims regarding Risperdal lawsuits and encourages those who believe they have developed gynecomastia or other injuries due to the use of Risperdal to speak with the lawyers at Wright & Schulte LLC by visiting yourlegalhelp.com or by calling 1-800-399-0795.

According to the Motion, the plaintiffs are alleging that Johnson & Johnson, as well as its subsidiary Janssen Pharmaceuticals, is failing to comply with the agreed-upon settlement. The reason for this noncompliance, according to the plaintiffs, is that the defendants are now trying to assert that this settlement should also resolve claims that have been filed against two other defendants – Exerpta Medica, Inc. and Elsevier, Inc. If these other claims are not resolved by the agreed-upon Risperdal settlement, then Johnson & Johnson has allegedly threatened to rescind the settlement deal.

In response, the plaintiffs are arguing in the motion that, for months, there have been various public assertions regarding the fact that the claims against Exerpta Medica and Elsevier are still valid and that Johnson & Johnson did not challenge such claims until late in September 2013. The plaintiffs are pointing to the facts that the other valid claims against Exerpta Medica and Elsevier were mentioned in several status conferences and that, in September, trial dates were actually set for these other claims.

Allegations in Risperdal Lawsuits Litigation

Risperdal, an atypical antipsychotic medication, has been approved by the FDA for the treatment of schizophrenia in adults and for bipolar disorder in children between the ages of 10 and 17 years old. While Risperdal has also been approved for the treatment of some of the symptoms of autism, it has reportedly also been prescribed for ADHD despite the fact it is not officially approved for the treatment of this condition.

Among the allegations in many Risperdal lawsuits are claims that the use of this drug has caused boys and men taking it to develop breast tissue. In some cases, breast tissue growth – which is clinically referred to as gynecomastia – has resulted in Risperdal patients developing breasts so large that they have had to undergo breast reduction surgery to get rid of these tissues. Despite undergoing breast reduction surgery, affected patients allegedly suffered psychological repercussions of having developed breasts, allege the Risperdal gynecomastia lawsuits. [medscape.com/viewarticle/571416_6, 2008]

In August 2012, Johnson & Johnson reportedly reached a $181 million Risperdal settlement with plaintiffs who had filed claims in state and federal courts. In these cases, the plaintiffs alleged Johnson & Johnson had promoted Risperdal for unapproved uses, including for the treatment of children, and that the company had failed to warn the public about the link between Risperdal and gynecomastia, as well as other Risperdal side effects.
[nytimes.com/2012/08/31/business/johnson-johnson-unit-settles-state-cases-over-risperdal.html?_r=1&, August 2012]

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

For current news on Risperdal lawsuits and Risperdal side-effects like our Risperdal Information page on Facebook.

Contact:
Wright & Schulte LLC
"An experienced harmful drug law firm"
1-800-399-0795
http://www.yourlegalhelp.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11343674.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
2. US Drug Watchdog Now Offers Victims Of A Transvaginal Mesh Product Failure A Unequaled Service By Offering the Names of Top Plaintiffs Attorneys-Who are all also Women
3. US Drug Watchdog Now Urges Transvaginal Mesh, Tape, or Bladder Sling Failure Victims To Call Them For the Names of Top Plaintiffs Women Attorneys--Erosion Is Not Normal
4. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
5. Imprelis Class Action Lawsuit Plaintiffs Could See Settlement Soon, Clients Can Opt-Out If Settlement Is Insufficient, Reports Wright & Sculte LLC
6. NuvaRing Lawsuits Move Forward, as Federal Judge Rules that Plaintiffs’ Experts May Testify on “Bursts” of Estrogen Allegedly Delivered by NuvaRing, Wright & Schulte LLC
7. Mirena IUD Lawyers at Gilman Law LLP, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Anticipates Progress in Newly Established Mirena Federal Litigation
8. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
9. C8 Lawsuits Move Forward, as Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in C8 Federal Litigation
10. DePuy ASR Hip Recall Lawsuits: Bernstein Liebhard LLP Notes Plaintiffs’ Opposition to Defense Motion on Punitive Damages in Federal DePuy ASR Lawsuits
11. DePuy ASR Hip Lawsuit Update: Federal ASR Hip Lawsuit Plaintiffs Oppose Punitive Damages Rules, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign that ... an app that lets users make and share payments through a smart device. In ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology: